文献速递糖尿病

二甲双胍治疗改善2型糖尿病患者角膜神经免疫异常

Metformin therapy modifies corneal neuroimmune abnormalities in people with type 2 diabetes.
PubMed 文献 · Diabetologia · 2025-03-07

本研究纳入36例接受二甲双胍治疗的2型糖尿病患者、36例年龄性别等匹配的未接受二甲双胍治疗的疾病对照及25例健康对照,比较角膜共聚焦显微镜与神经传导检查结果。结果显示二甲双胍组角膜神经纤维密度、长度及分形维数更高,下涡旋树突状细胞密度更低;二甲双胍治疗与更优的角膜神经参数及神经免疫张力相关,可能具有神经保护作用。

要点

  • 二甲双胍组角膜神经纤维密度、长度及分形维数均高于非二甲双胍组。
  • 二甲双胍组下涡旋树突状细胞密度显著低于非二甲双胍组。
  • 二甲双胍治疗与更优的角膜神经参数及神经免疫张力相关。

核心结论

  • 二甲双胍治疗与2型糖尿病患者角膜上皮下神经丛更优的神经参数及神经免疫张力相关,研究进一步提示二甲双胍可能对糖尿病周围神经病变具有神经保护作用。

研究设计与样本

  • 研究纳入36例接受二甲双胍治疗的2型糖尿病患者,并行临床评估、角膜共聚焦显微镜及神经传导检查。
  • 另选36例未接受二甲双胍治疗的2型糖尿病患者作为疾病对照,按年龄、性别、糖尿病病程、BMI、eGFR、HbA1c、其他口服降糖药及代谢综合征治疗药物与二甲双胍组匹配。
  • 另评估25例健康对照,按年龄和性别匹配。
  • 回顾分析所有2型糖尿病患者过去20年病历中既往及当前二甲双胍使用情况。

主要发现

  • 接受二甲双胍治疗者角膜神经纤维密度高于未接受二甲双胍治疗者(p=0.020)。
  • 接受二甲双胍治疗者角膜神经纤维长度高于未接受二甲双胍治疗者(p=0.020)。
  • 接受二甲双胍治疗者角膜分形维数高于未接受二甲双胍治疗者(p=0.003)。
  • 二甲双胍组下涡旋树突状细胞密度显著低于非二甲双胍组(p=0.043)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Diabetic peripheral neuropathy is a debilitating microvascular complication of diabetes mellitus, with limited disease-modifying therapies to date. This study aimed to assess the effect of metformin on the corneal sub-basal nerve plexus as a peripheral neuropathy outcome measure in people with type 2 diabetes. METHODS: A cohort of 36 participants with type 2 diabetes receiving metformin therapy were recruited and underwent clinical assessment, corneal confocal microscopy and nerve conduction studies. Concurrently, 36 participants with type 2 diabetes not receiving metformin therapy were selected as disease controls and matched to participants on metformin therapy for age, sex, diabetes duration, BMI, eGFR, HbA1c, use of other oral glucose-lowering agents and therapies used for the treatment of the metabolic syndrome. Additionally, 25 healthy control participants were assessed and matched for age and sex. Medical record data over the previous 20 years were analysed for prior and current metformin use in all participants with type 2 diabetes. RESULTS: Participants receiving metformin therapy had higher corneal nerve fibre density (p=0.020), corneal nerve fibre length (p=0.020) and corneal fractal dimension (p=0.003) compared with those not receiving metformin therapy. The inferior whorl dendritic cell density was significantly lower in the metformin group compared with the non-metformin group (p=0.043). CONCLUSIONS/INTERPRETATION: Metformin treatment is associated with superior corneal nerve parameters and neuroimmune tone in the corneal sub-basal nerve plexus. This study provides further evidence that metformin may be neuroprotective in diabetic peripheral neuropathy.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Tsoi AT, Sng J, Tummanapalli SS, et al. Metformin therapy modifies corneal neuroimmune abnormalities in people with type 2 diabetes. Diabetologia. 2025. PMID: 40053106. doi:10.1007/s00125-025-06399-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。